The chaperone-like protein 14-3-3h interacts with human a-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing a-synuclein cellular toxicity

Human Molecular Genetics

Volumn 23, Issue 21, 2014, Pages 5615-5629

  Plotegher, Nicoletta ^a   Kumar, Dhruv ^b   Tessari, Isabella ^a   Brucale, Marco ^b,c   Munari, Francesca ^a   Tosatto, Laura ^a   Belluzzi, Elisa ^a   Greggio, Elisa ^a   Bisaglia, Marco ^a   Capaldi, Stefano ^d   Aioanei, Daniel ^b   Mammi, Stefano ^a   Monaco, Hugo L ^d   Samori, Bruno ^b   Bubacco, Luigi ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

14 3 3 ETA CHAPERONE LIKE PROTEIN; ALPHA SYNUCLEIN; ENHANCED GREEN FLUORESCENT PROTEIN; PROTEIN; PROTEIN 14 3 3; UNCLASSIFIED DRUG; ISOPROTEIN; PROTEIN BINDING;

ARTICLE; CELL AGGREGATION; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE POLARIZATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; STOICHIOMETRY; X RAY CRYSTALLOGRAPHY; AMYLOIDOSIS; CHEMISTRY; GENETICS; KINETICS; METABOLISM; PROTEINOSIS; SIGNAL TRANSDUCTION;

14-3-3 PROTEINS; ALPHA-SYNUCLEIN; AMYLOIDOSIS; HUMANS; KINETICS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 84911388014     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu275     Document Type: Article

References (75)

1. de Lau, L.M. and Breteler, M.M. (2006) Epidemiology of Parkinson's disease. Lancet Neurol., 5, 525-535.
2. Hirsch, E., Graybiel, A.M. and Agid, Y.A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature, 334, 345-348.
3. Puschmann, A. (2013) Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat. Disord., 19, 407-415.
4. Kara, E., Lewis, P.A., Ling, H., Proukakis, C., Houlden, H. and Hardy, J. (2013) Alpha-synuclein mutations cluster around a putative protein loop. Neurosci. Lett., 546, 67-70.
5. Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A.J., Hardy, J. et al. (2013) Alpha-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol., 125, 753-769.
6. Kasten, M. and Klein, C. (2013) The many faces of alpha-synuclein mutations. Mov. Disord., 28, 697-701.
7. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
8. Plotegher, N., Greggio, E., Bisaglia, M. and Bubacco, L. (2014) Biophysical groundwork as a hinge to unravel the biology of alpha-synuclein aggregation and toxicity. Q. Rev. Biophys., 47, 1-48.
9. Uversky, V.N. (2011) Intrinsically disordered proteins from A to Z. Int. J. Biochem. Cell Biol., 43, 1090-1103.
10. Uversky, V.N. and Dunker, A.K. (2010) Understanding protein non-folding. Biochim. Biophys. Acta, 1804, 1231-1264.
11. Dyson, H.J. (2011) Expanding the proteome: disordered and alternatively folded proteins. Q. Rev. Biophys., 44, 467-518.
12. Bartels, T., Ahlstrom, L.S., Leftin, A., Kamp, F., Haass, C., Brown, M.F. and Beyer, K. (2010) The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys. J., 99, 2116-2124.
13. Bartels, T., Choi, J.G. and Selkoe, D.J. (2011) Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 477, 107-110.
14. Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L.T., Liao, J., Auclair, J.R., Johnson, D., Landeru, A., Simorellis, A.K. et al. (2011) A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl Acad. Sci. USA, 108, 17797-17802.
15. Fauvet, B., Mbefo, M.K., Fares, M.B., Desobry, C., Michael, S., Ardah, M.T., Tsika, E., Coune, P., Prudent, M., Lion, N. et al. (2012) Alpha-synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem., 287, 15345-15364.
16. Scott, D. and Roy, S. (2012) Alpha-synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J. Neurosci., 32, 10129-10135.
17. Clayton, D.F. and George, J.M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci., 21, 249-254.
18. Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R. and Sudhof, T.C. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 329, 1663-1667.
19. Knowles, T.P., White, D.A., Abate, A.R., Agresti, J.J., Cohen, S.I., Sperling, R.A., De Genst, E.J., Dobson, C.M. and Weitz, D.A. (2011) Observation of spatial propagation of amyloid assembly from single nuclei. Proc. Natl Acad. Sci. USA, 108, 14746-14751.
20. Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M. and Biere, A.L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem., 274, 19509-19512.
21. Conway, K.A., Harper, J.D. and Lansbury, P.T. Jr. (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-2563.
22. Bisaglia, M., Mammi, S. and Bubacco, L. (2009) Structural insights on physiological functions and pathological effects of alpha-synuclein. FASEB J., 23, 329-340.
23. Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S. et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA, 108, 4194-4199.
24. Lashuel, H.A., Petre, B.M., Wall, J., Simon, M., Nowak, R.J., Walz, T. and Lansbury, P.T. Jr. (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol., 322, 1089-1102.
25. Kim, H.Y., Cho, M.K., Kumar, A., Maier, E., Siebenhaar, C., Becker, S., Fernandez, C.O., Lashuel, H.A., Benz, R., Lange, A. et al. (2009) Structural properties of pore-forming oligomers of alpha-synuclein. J. Am. Chem. Soc., 131, 17482-17489.
26. Luk, K.C., Song, C., O'Brien, P., Stieber, A., Branch, J.R., Brunden, K.R., Trojanowski, J.Q. and Lee, V.M. (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA, 106, 20051-20056.
27. Bandopadhyay, R. and de Belleroche, J. (2010) Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. Trends Mol. Med., 16, 27-36.
28. Dedmon, M.M., Christodoulou, J., Wilson, M.R. and Dobson, C.M. (2005) Heat shock protein 70 inhibits alpha-synucleinfibril formation via preferential binding to prefibrillar species. J. Biol. Chem., 280, 14733-14740.
29. Waudby, C.A., Knowles, T.P., Devlin, G.L., Skepper, J.N., Ecroyd, H., Carver, J.A., Welland, M.E., Christodoulou, J., Dobson, C.M. and Meehan, S. (2010) The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation. Biophys. J., 98, 843-851.
30. Shendelman, S., Jonason, A., Martinat, C., Leete, T. and Abeliovich, A. (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol., 2, e362.
31. Duennwald, M.L. and Shorter, J. (2010) Countering amyloid polymorphism and drug resistance with minimal drug cocktails. Prion, 4, 244-251.
32. Ebrahimi-Fakhari, D., Wahlster, L. and McLean, P.J. (2011) Molecular chaperones in Parkinson's Disease-present and future. J. Parkinsons Dis., 1, 299-320.
33. Duennwald, M.L., Echeverria, A. and Shorter, J. (2012) Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol., 10, e1001346.
34. Berg, D., Holzmann, C. and Riess, O. (2003) 14-3-3 proteins in the nervous system. Nat. Rev. Neurosci., 4, 752-762.
35. Bustos, D.M. and Iglesias, A.A. (2006) Intrinsic disorder is a key characteristic in partners that bind 14-3-3 proteins. Proteins, 63, 35-42.
36. Yang, X., Lee, W.H., Sobott, F., Papagrigoriou, E., Robinson, C.V., Grossmann, J.G., Sundstrom, M., Doyle, D.A. and Elkins, J.M. (2006) Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc. Natl Acad. Sci. USA, 103, 17237-17242.
37. Coblitz, B., Wu, M., Shikano, S. and Li, M. (2006) C-terminal binding: an expanded repertoire and function of 14-3-3 proteins. FEBS Lett., 580, 1531-1535.
38. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J. and Wolozin, B. (1999) Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci., 19, 5782-5791.
39. Nichols, R.J., Dzamko, N., Morrice, N.A., Campbell, D.G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A.R. et al. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J., 430, 393-404.
40. Sato, S., Chiba, T., Sakata, E., Kato, K., Mizuno, Y., Hattori, N. and Tanaka, K. (2006) 14-3-3eta is a novel regulator of parkin ubiquitin ligase.EMBOJ., 25, 211-221.
41. Kawamoto, Y., Akiguchi, I., Nakamura, S., Honjyo, Y., Shibasaki, H. and Budka, H. (2002) 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J. Neuropathol. Exp. Neurol., 61, 245-253.
42. Umahara, T., Uchihara, T. and Iwamoto, T. (2012) Structure-oriented review of 14-3-3 protein isoforms in geriatric neuroscience. Geriatr. Gerontol. Int., 12, 586-599.
43. Shirakashi, Y., Kawamoto, Y., Tomimoto, H., Takahashi, R. and Ihara, M. (2006) Alpha-synuclein is colocalized with 14-3-3 and synphilin-1 in A53 T transgenic mice. Acta Neuropathol., 112, 681-689.
44. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W. and Yankner, B.A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med., 8, 600-606.
45. Yacoubian, T.A., Slone, S.R., Harrington, A.J., Hamamichi, S., Schieltz, J.M., Caldwell, K.A., Caldwell, G.A. and Standaert, D.G. (2010) Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death Dis., 1, e2.
46. Luk, K.C., Hyde, E.G., Trojanowski, J.Q. and Lee, V.M. (2007) Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors. Biochemistry, 46, 12522-12529.
47. Segers-Nolten, I., van der Werf, K., van Raaij, M. and Subramaniam, V. (2007) Quantitative characterization of protein nanostructures using atomic force microscopy. Conf. Proc. IEEE Eng. Med. Biol. Soc., 2007, 6609-6612.
48. Sweers, K.K., van der Werf, K.O., Bennink, M.L. and Subramaniam, V. (2012) Atomic force microscopy under controlled conditions reveals structure of C-terminal region of alpha-synuclein in amyloid fibrils. ACS Nano, 6, 5952-5960.
49. Waxman, E.A. and Giasson, B.I. (2010) A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J. Neurochem., 113, 374-388.
50. Nonaka, T., Watanabe, S.T., Iwatsubo, T. and Hasegawa, M. (2010) Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem., 285, 34885-34898.
51. Berg, D., Riess, O. and Bornemann, A. (2003) Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol, 54, 135.
52. Ubl, A., Berg, D., Holzmann, C., Kruger, R., Berger, K., Arzberger, T., Bornemann, A. and Riess, O. (2002) 14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta. Brain Res. Mol. Brain Res, 108, 33-39.
53. Kurz, A., May, C., Schmidt, O., Muller, T., Stephan, C., Meyer, H.E., Gispert, S., Auburger, G. and Marcus, K. (2012) A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. J. Neural Transm. Supp., 119, 297-312.
54. Qin, Z., Hu, D., Han, S., Hong, D.P. and Fink, A.L. (2007) Role of different regions of alpha-synuclein in the assembly of fibrils. Biochemistry, 46, 13322-13330.
55. Giehm, L., Svergun, D.I., Otzen, D.E. and Vestergaard, B. (2011) Low-resolution structure of a vesicle disrupting a-synuclein oligomer that accumulates during fibrillation. Proc. Natl Acad. Sci.USA, 108, 3246-3251.
56. Cremades, N., Cohen, S.I., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal, M., Clarke, R.W., Dunne, P., Aprile, F.A. et al. (2012) Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell, 149, 1048-1059.
57. Zijlstra, N., Blum, C., Segers-Nolten, I.M., Claessens, M.M. and Subramaniam, V. (2012) Molecular composition of sub-stoichiometrically labeled alpha-synuclein oligomers determined by single-molecule photobleaching. Angew. Chem. Int. Ed Engl., 51, 8821-8824.
58. Luk, K.C., Mills, I.P., Trojanowski, J.Q. and Lee, V.M. (2008) Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. Biochemistry, 47, 12614-12625.
59. Waxman, E.A., Mazzulli, J.R. and Giasson, B.I. (2009) Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. Biochemistry, 48, 9427-9436.
60. Roberti, M.J., Jovin, T.M. and Jares-Erijman, E. (2011) Confocal fluorescence anisotropy and FRAP imaging of alpha-synuclein amyloid aggregates in living cells. PLoS ONE, 6, e23338.
61. Outeiro, T.F., Putcha, P., Tetzlaff, J.E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B.T. and McLean, P.J. (2008) Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE, 3, e1867.
62. Plotegher, N., Gratton, E. and Bubacco, L. (2014) Number and brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim. Biophys. Acta., 1840, 2014-2024.
63. Olzscha, H., Schermann, S.M., Woerner, A.C., Pinkert, S., Hecht, M.H., Tartaglia, G.G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F.U. and Vabulas, R.M. (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell, 144, 67-78.
64. Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q. and Lee, V.M. (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338, 949-953.
65. Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A., Meaney, D.F., Trojanowski, J.Q. and Lee, V.M. (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron, 72, 57-71.
66. Omi, K., Hachiya, N.S., Tanaka, M., Tokunaga, K. and Kaneko, K. (2008) 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein. Neurosci. Lett., 431, 45-50.
67. Sluchanko, N.N. and Gusev, N.B. (2011) Probable participation of 14-3-3 in tau protein oligomerization and aggregation. J. Alzheimers Dis., 27, 467-476.
68. Huang, C., Ren, G., Zhou, H. and Wang, C.C. (2005) A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr. Purif., 42, 173-177.
69. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR, 6, 277-293.
70. LeVine, H. III. (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci., 2, 404-410.
71. Abramoff, M.D., Magelhaes, P.J. and Ram, S.J. (2004) Image processing with ImageJ. Biophotonics Int, 11, 36-42.
72. Sternberg, S.R. (1983) Biomedical image processing. Computer, 16, 22-34.
73. Zhang, T.Y. (1984)A fast parallel algorithm for thinning digital patterns[J]. Communications of ACM, 27, 236-239.
74. Kang, H.W. (2005) G-wire: A livewire segmentation algorithm based on a generalized graph formulation. Pattern Recognition Letters, 26, 2042-2051.
75. Kang, H.W. and Shin, S.Y. (2002) Enhanced lane: interactive image segmentation by incremental path map construction. Graphical Models, 64, 282-303.